Botulinum toxin A injection for post-stroke upper limb spasticity and rehabilitation practices from centers across Asian countries.

Describe real-life practice and outcomes in the management of post-stroke upper limb spasticity with botulinum toxin A (BoNT-A) in Asian settings. Subgroup analysis of a prospective, observational study (NCT01020500) of adult patients (≥18 years) with post-stroke upper limb spasticity presenting for routine spasticity management, including treatment with BoNT-A. The primary outcome was goal attainment as assessed using goal-attainment scaling (GAS). Patients baseline clinical characteristics and BoNT-A injection parameters are also described. Overall, 51 patients from Asia were enrolled. Rates of comorbid cognitive and emotional problems were relatively low. Patients tended to have more severe distal limb spasticity and to prioritize active over passive function goals. Most (94.1%) patients in the subgroup were treated with abobotulinumtoxinA. For these patients, the median total dose was 500 units, and the most frequently injected muscles were the biceps brachii (83.3%), flexor carpi radialis (72.9%), and flexor digitorum profundus (66.7%). Overall, 74.5% achieved their primary goal and the mean GAS T score after one treatment cycle was 56.0 ± 13.0, with a change from baseline of 20.9 ± 14.3 ( In the Asian treatment setting, BoNT-A demonstrated a clinically significant effect on goal attainment for the real-life management of upper limb spasticity following stroke.

Informations de copyright

Copyright © 2024 Rosales, Chia, Kumthornthip, Goh, Mak, Kong, Ng, Chou, Flordelis, Do, Maisonobe, Li and Suputtitada.

Déclaration de conflit d'intérêts

RR reports being a clinical trialist for Ipsen on BoNT-A applications for Cervical Dystonia and Post-Stroke Spasticity. In the past, he was engaged in an Allergan BoNT-A Cervical Dystonia Trial. He has received travel honoraria for lectures on BoNT-A for Ipsen, Allergan and Merz. NC was employed by Ipsen at the time of study. AS has received travel honoraria for lectures on BoNT-A from medical congresses. TD and PM were employed by Ipsen. The authors declare that this study received funding from Ipsen who were involved in the study design, collection, and data analysis. The funder was not involved in the interpretation of data, the writing of this article, or the decision to submit it for publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.